0
Articles |

Cardiovascular Safety of High Doses of Inhaled Fenoterol and Albuterol in Acute Severe Asthma FREE TO VIEW

Michael T. Newhouse; Kenneth R. Chapman; Andrew L. McCallum; Raja T. Abboud; Dennis M. Bowie; Richard V. Hodder; Peter D. Paré; Hilda Mesic-Fuchs; Nestor A. Molfino
Author and Funding Information

Affiliations: From McMaster University, and Barnett Medical Aerosol Research Laboratory, St. Joseph's Hospital, Hamilton, Ontario,  From the University of Toronto, The Toronto Hospital, Toronto, Ontario,  From the University of Toronto, Faculty of Medicine, Sunnybrook Health Science Centre, North York, Ontario,  From the Department of Medicine, University of British Columbia, Vancouver General Hospital, Vancouver, BC,  From the University Faculty of Medicine, Dalhousie University, Victoria General Hospital, Halifax, Nova Scotia,  From the Department of Medicine, University of Ottawa, Ottawa Civic Hospital, Ottawa, Ontario,  From the University of British Columbia, St. Paul's Hospital, Vancouver, BC,  From the Boehringer Ingelheim (Canada) Ltd,  From the Department of Medicine, University of Toronto, Ontario

Affiliations: From McMaster University, and Barnett Medical Aerosol Research Laboratory, St. Joseph's Hospital, Hamilton, Ontario,  From the University of Toronto, The Toronto Hospital, Toronto, Ontario,  From the University of Toronto, Faculty of Medicine, Sunnybrook Health Science Centre, North York, Ontario,  From the Department of Medicine, University of British Columbia, Vancouver General Hospital, Vancouver, BC,  From the University Faculty of Medicine, Dalhousie University, Victoria General Hospital, Halifax, Nova Scotia,  From the Department of Medicine, University of Ottawa, Ottawa Civic Hospital, Ottawa, Ontario,  From the University of British Columbia, St. Paul's Hospital, Vancouver, BC,  From the Boehringer Ingelheim (Canada) Ltd,  From the Department of Medicine, University of Toronto, Ontario

Affiliations: From McMaster University, and Barnett Medical Aerosol Research Laboratory, St. Joseph's Hospital, Hamilton, Ontario,  From the University of Toronto, The Toronto Hospital, Toronto, Ontario,  From the University of Toronto, Faculty of Medicine, Sunnybrook Health Science Centre, North York, Ontario,  From the Department of Medicine, University of British Columbia, Vancouver General Hospital, Vancouver, BC,  From the University Faculty of Medicine, Dalhousie University, Victoria General Hospital, Halifax, Nova Scotia,  From the Department of Medicine, University of Ottawa, Ottawa Civic Hospital, Ottawa, Ontario,  From the University of British Columbia, St. Paul's Hospital, Vancouver, BC,  From the Boehringer Ingelheim (Canada) Ltd,  From the Department of Medicine, University of Toronto, Ontario

Affiliations: From McMaster University, and Barnett Medical Aerosol Research Laboratory, St. Joseph's Hospital, Hamilton, Ontario,  From the University of Toronto, The Toronto Hospital, Toronto, Ontario,  From the University of Toronto, Faculty of Medicine, Sunnybrook Health Science Centre, North York, Ontario,  From the Department of Medicine, University of British Columbia, Vancouver General Hospital, Vancouver, BC,  From the University Faculty of Medicine, Dalhousie University, Victoria General Hospital, Halifax, Nova Scotia,  From the Department of Medicine, University of Ottawa, Ottawa Civic Hospital, Ottawa, Ontario,  From the University of British Columbia, St. Paul's Hospital, Vancouver, BC,  From the Boehringer Ingelheim (Canada) Ltd,  From the Department of Medicine, University of Toronto, Ontario

Affiliations: From McMaster University, and Barnett Medical Aerosol Research Laboratory, St. Joseph's Hospital, Hamilton, Ontario,  From the University of Toronto, The Toronto Hospital, Toronto, Ontario,  From the University of Toronto, Faculty of Medicine, Sunnybrook Health Science Centre, North York, Ontario,  From the Department of Medicine, University of British Columbia, Vancouver General Hospital, Vancouver, BC,  From the University Faculty of Medicine, Dalhousie University, Victoria General Hospital, Halifax, Nova Scotia,  From the Department of Medicine, University of Ottawa, Ottawa Civic Hospital, Ottawa, Ontario,  From the University of British Columbia, St. Paul's Hospital, Vancouver, BC,  From the Boehringer Ingelheim (Canada) Ltd,  From the Department of Medicine, University of Toronto, Ontario

Affiliations: From McMaster University, and Barnett Medical Aerosol Research Laboratory, St. Joseph's Hospital, Hamilton, Ontario,  From the University of Toronto, The Toronto Hospital, Toronto, Ontario,  From the University of Toronto, Faculty of Medicine, Sunnybrook Health Science Centre, North York, Ontario,  From the Department of Medicine, University of British Columbia, Vancouver General Hospital, Vancouver, BC,  From the University Faculty of Medicine, Dalhousie University, Victoria General Hospital, Halifax, Nova Scotia,  From the Department of Medicine, University of Ottawa, Ottawa Civic Hospital, Ottawa, Ontario,  From the University of British Columbia, St. Paul's Hospital, Vancouver, BC,  From the Boehringer Ingelheim (Canada) Ltd,  From the Department of Medicine, University of Toronto, Ontario

Affiliations: From McMaster University, and Barnett Medical Aerosol Research Laboratory, St. Joseph's Hospital, Hamilton, Ontario,  From the University of Toronto, The Toronto Hospital, Toronto, Ontario,  From the University of Toronto, Faculty of Medicine, Sunnybrook Health Science Centre, North York, Ontario,  From the Department of Medicine, University of British Columbia, Vancouver General Hospital, Vancouver, BC,  From the University Faculty of Medicine, Dalhousie University, Victoria General Hospital, Halifax, Nova Scotia,  From the Department of Medicine, University of Ottawa, Ottawa Civic Hospital, Ottawa, Ontario,  From the University of British Columbia, St. Paul's Hospital, Vancouver, BC,  From the Boehringer Ingelheim (Canada) Ltd,  From the Department of Medicine, University of Toronto, Ontario

Affiliations: From McMaster University, and Barnett Medical Aerosol Research Laboratory, St. Joseph's Hospital, Hamilton, Ontario,  From the University of Toronto, The Toronto Hospital, Toronto, Ontario,  From the University of Toronto, Faculty of Medicine, Sunnybrook Health Science Centre, North York, Ontario,  From the Department of Medicine, University of British Columbia, Vancouver General Hospital, Vancouver, BC,  From the University Faculty of Medicine, Dalhousie University, Victoria General Hospital, Halifax, Nova Scotia,  From the Department of Medicine, University of Ottawa, Ottawa Civic Hospital, Ottawa, Ontario,  From the University of British Columbia, St. Paul's Hospital, Vancouver, BC,  From the Boehringer Ingelheim (Canada) Ltd,  From the Department of Medicine, University of Toronto, Ontario

Affiliations: From McMaster University, and Barnett Medical Aerosol Research Laboratory, St. Joseph's Hospital, Hamilton, Ontario,  From the University of Toronto, The Toronto Hospital, Toronto, Ontario,  From the University of Toronto, Faculty of Medicine, Sunnybrook Health Science Centre, North York, Ontario,  From the Department of Medicine, University of British Columbia, Vancouver General Hospital, Vancouver, BC,  From the University Faculty of Medicine, Dalhousie University, Victoria General Hospital, Halifax, Nova Scotia,  From the Department of Medicine, University of Ottawa, Ottawa Civic Hospital, Ottawa, Ontario,  From the University of British Columbia, St. Paul's Hospital, Vancouver, BC,  From the Boehringer Ingelheim (Canada) Ltd,  From the Department of Medicine, University of Toronto, Ontario


1996 by the American College of Chest Physicians


Chest. 1996;110(3):595-603. doi:10.1378/chest.110.3.595
Text Size: A A A
Published online

Abstract

Background: It has been suggested that overuse of fenoterol metered-dose inhalers (MDIs) may increase the risk of death from asthma due to cardiac arrhythmias. Our primary objective was to compare the cardiovascular safety of fenoterol and albuterol MDIs when administered in maximal bronchodilating or maximal tolerated doses to an absolute maximum of 16 puffs, for the emergency department (ED) treatment of acute severe asthma.

Methods: Asthmatic patients presenting to the ED with acute severe asthma (FEV1 less than 50% of predicted) were enrolled in a multicenter, randomized, double-blind, parallel-group study. Following baseline measurements, (medical history, physical examination, determination of serum potassium and serum theophylline levels, oximetry, 12-lead ECG, and spirometry), each patient received 4 puffs of either fenoterol, 200 µg per puff, or albuterol, 100 µg per puff, 1 puff every 30 s via an MDI attached to a holding chamber. Additional doses of inhaled β2-agonist were administered by dose titration, 2 puffs every 10 min to a maximal cumulative dose of 16 puffs of albuterol or fenoterol, side effects were intolerable to the patient, or an FEV1 plateau (ie, <10% improvement for 2 consecutive doses) occurred. ECG was recorded continuously via Holter monitor, and respiratory rate, BP, dyspnea (Borg scale), and FEV1 were assessed after each dose.

Results: 128 patients were randomized to receive fenoterol and 129 to receive albuterol. Overall, fenoterol increased FEV1 160 mL more than albuterol. The mean (SEM) FEV1 increase from baseline was 0.75±0.06 L in the fenoterol group and 0.59±0.06 L in the albuterol group (p<0.03). Both β2-agonists caused a decrease in serum potassium level that was significantly greater in the fenoterol (0.23±0.04 mmol/L) than in the salbutamol (0.06±0.03 mmol/L) group (p=0.0002). There was also a greater increase in the Q-Tc interval in the fenoterol group, 0.011±0.003 s compared with 0.003±0.003 s in the albuterol group (p<0.05). Differences in hypokalemia and Q-Tc prolongation associated with fenoterol and albuterol were significantly different only after 8 puffs of fenoterol had been given. 32 patients exhibited ventricular premature beats, 14 in the fenoterol group and 18 in the albuterol group. There were 34 patients with episodes of supraventricular premature beats, 17 in each group. No episodes of sustained ventricular tachycardia were detected in either group.

Conclusions: In adequately oxygenated patients, using dose titration of fenoterol, in a formulation of 200 µg per puff by MDI valved holding chamber and mask, to a total dose of 3,200 µg and salbutamol (100 µg per puff) to a total dose of 1,600 µg over 90 min, showed cardiovascular safety in acute severe asthma. This was evidenced by absence of cardiovascular mortality or clinically significant arrhythmias in either group. The 100% greater dose of fenoterol improved FEV1 significantly more than salbutamol and was associated with a relatively small but significantly greater prolongation of the Q-Tc interval and decrease in serum potassium level. This study does not exclude the possibility that adverse cardiac events could occur with severe hypoxemia.


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Guidelines
Treatment of acute exacerbation of asthma.
Finnish Medical Society Duodecim | 1/25/2008
Long-term management of asthma.
Finnish Medical Society Duodecim | 1/11/2008
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543